Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
0vC7uRXuLswads4W
